Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
ADPT Form 144 notice lists proposed sales of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing shows a proposed sale dated 03/03/2026 tied to an exercise of stock options for 1,037,487 shares and earlier restricted stock units dated 03/04/2022 for 169,174 shares. The securities are listed on NASDAQ.
Harlan Robins reported multiple sales of Common Stock under Form 144, and lists restricted shares acquired as compensation.
The filing shows securities to be sold include 10,000 Common Stock shares acquired as Restricted Stock Units on 03/06/2023 as compensation. The sale activity includes multiple disposals on 12/03/2025, 12/04/2025, 01/06/2026, and early February–March 2026, including transactions of 27,212 shares on 12/03/2025 and 32,273 shares on 02/02/2026.
Adaptiiv, Inc. (ADPT) reporting person Chad M. Robins submitted Form 144 to sell common stock. The filing lists multiple proposed sales on several dates with individual lots shown by share count and proceeds. Examples include sales of 99,225 shares on 02/27/2026 and 41,666 shares on 01/05/2026.
Adaptive Biotechnologies (ADPT) insider Chad M. Robins reported multiple proposed sales of Common Stock under Rule 144. The excerpt lists repeated dispositions of 41,666 shares on 11/26/2025, 12/01/2025, 01/05/2026 and 02/02/2026, plus a 35,736-share entry on 11/26/2025. Each row shows a gross sale amount in dollars alongside the share counts.
Adaptive Biotechnologies reported strong 2025 growth driven by its MRD business. Revenue reached $277.0 million, up from $179.0 million in 2024, with MRD revenue of $212.3 million, a 46% increase. clonoSEQ test volume rose to 105,587 tests, up 39% year-over-year.
Net cash used in operations fell to $46.0 million from $95.2 million, while cash, cash equivalents and marketable securities totaled $227.2 million as of December 31, 2025. The company also highlighted growing payor coverage, extensive MRD use in over 180 active trials and new IM data and partnerships, including non‑exclusive agreements with Pfizer.
Adaptive Biotechnologies Chief Financial Officer Kyle Piskel reported routine share transactions under a pre-set trading plan. On February 4, 2026, he exercised 2,145 stock options at $12.14 per share and acquired the same number of common shares.
That same day, he sold 2,145 common shares at $18.46 per share under a Rule 10b5-1 trading plan adopted on August 28, 2025. Following these transactions, he directly owned 216,637 shares of common stock and 2,146 stock options. The options originally vested 25% on March 4, 2023, with the remainder vesting monthly thereafter.
Adaptive Biotechnologies Corporation furnished an update on its financial performance by issuing a press release covering results for the quarter and fiscal year ended December 31, 2025. The company submitted this current report to make that earnings release available to investors and attached it as Exhibit 99.1.
The press release with detailed financial figures and commentary is incorporated by reference but is expressly treated as "furnished" rather than "filed" under securities laws, which affects how it is used in certain legal contexts and other regulatory filings.
Adaptive Biotechnologies’ Chief Scientific Officer, Harlan S. Robins, reported preset stock sales under a Rule 10b5-1 trading plan. On February 2, 2026, he sold 34,668 shares of common stock at a weighted average price of $18.60, followed by a sale of 8,120 shares on February 3, 2026 at a weighted average price of $19.00.
The filing notes these trades were executed under a trading plan adopted on August 11, 2025, and that each reported price reflects multiple trades within stated ranges. After these transactions, Robins beneficially owned 1,179,524 shares of Adaptive Biotechnologies common stock directly.
Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported a planned stock sale. On February 2, 2026, he sold 124,998 shares of Common Stock at a weighted average price of $18.44 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on August 11, 2025.
After this sale, Robins beneficially owned 2,459,245 shares of Adaptive Biotechnologies Common Stock in direct form.